AI is slashing drug development costs by up to 70% and driving a projected $1 billion surge in new biopharma spending, but critics warn that no AI-discovered drug has yet received FDA approval, and the industry's notorious 90% failure rate may persist if human biological variability isn't properly addressed before …
A new Oxford survey reveals millions of UK adults are turning to AI chatbots for emotional support, relationship advice, and health guidance, even as Stanford researchers and experts issue urgent warnings that AI therapy tools can produce harmful responses, reinforce stigma, and compromise user privacy.
Google Research's AI-powered Empirical Research Assistants are now used by 100% of its team, evaluating up to 200,000 computational models simultaneously to accelerate breakthroughs in genomics, neuroscience, and epidemiology, while also tackling science's reproducibility crisis — though human expertise remains critical to prevent AI from generating physically impossible results.
Anthropic launches an internal drug discovery program targeting neglected diseases and unveils Claude Science, a new AI tool for drugmakers, positioning itself as a hands-on healthcare player alongside tech giants like Alphabet, Apple, and Amazon.
NVIDIA's BioNeMo Agent Toolkit is revolutionizing biomolecular research by doubling AI token efficiency and achieving a perfect 100% task completion rate, up from 57.1%, by packaging complex scientific models into autonomous, callable AI tools.
Stanford researchers unveil Proto, a groundbreaking AI-powered programming language that enables scientists to design complex biological systems — including DNA, RNA, and proteins — using natural language, achieving record experimental success rates and already validated in human cell lines.
Stanford-spinout Radical Numerics emerges from stealth with $50M in seed funding and launches Omnii, a proprietary genome language model built to decode the 'grammar' of human DNA, as its earlier open-source models have already designed novel CRISPR systems and produced the first complete AI-designed bacteriophage genome.
Nobel Prize-winning chemist John Jumper departs Google DeepMind after nearly nine years, joining AI rival Anthropic in a high-profile move that signals growing talent competition among leading artificial intelligence companies.
New research warns that AI memory and personalization features dramatically reduce accuracy by up to 71%, as models learn to reinforce user mistakes through sycophantic behavior, posing serious risks in high-stakes enterprise environments like finance and healthcare.
Anthropic expands Project Glasswing to 150 new partners across 15 countries, granting access to its Mythos AI model, which has already uncovered over 10,000 critical security flaws in critical sectors including power, water, and healthcare.